Huntington's disease is a multi-system disorder

被引:45
|
作者
Mielcarek, Michal [1 ]
机构
[1] Imperial Coll London, Dept Life Sci, London, England
基金
欧洲研究理事会;
关键词
cardiomyopathy; Huntington's disease; neurodegeneration; peripheral tissue pathology; skeletal muscle atrophy; triplet repeat disorder;
D O I
10.1080/21675511.2015.1058464
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Huntington's disease (HD) is one of the most common non-curable rare diseases and is characterized by choreic movements, psychiatric symptoms, and slowly progressive dementia. HD is inherited as an autosomal dominant disorder with complete penetrance. Although brain pathology has become a hallmark of HD, there is a critical mass of new studies suggesting peripheral tissue pathology as an important factor in disease progression. In particular, recently published studies about skeletal muscle malfunction and HD-related cardiomyopathy in HD mouse models strongly suggest their important roles, leading to upcoming preclinical and clinical trials. One might conclude that therapeutic approaches in HD should not be restricted only to the brain pathology but instead major efforts should also be made to understand the cross-talk between diseased tissues like the CNS-Heart or CNS-skeletal muscle axes.
引用
收藏
页数:3
相关论文
共 50 条
  • [1] The Endocannabinoid System and Huntington's Disease
    Lastres-Becker, I
    De Miguel, R.
    Fernandez-Ruiz, J. J.
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2003, 2 (05) : 335 - 347
  • [2] Circadian and sleep disorder in Huntington's disease
    Morton, A. Jennifer
    EXPERIMENTAL NEUROLOGY, 2013, 243 : 34 - 44
  • [3] Huntington's disease: Neuropsychiatric manifestations of Huntington's disease
    Goh, Anita M. Y.
    Wibawa, Pierre
    Loi, Samantha M.
    Walterfang, Mark
    Velakoulis, Dennis
    Looi, Jeffrey C. L.
    AUSTRALASIAN PSYCHIATRY, 2018, 26 (04) : 366 - 375
  • [4] Primary Pulmonary Hypertension as a Manifestation of Adult Multi-System Mitochondrial Disorder
    Finsterer, Josef
    YONSEI MEDICAL JOURNAL, 2009, 50 (02) : 307 - 308
  • [5] The endocannabinoid system in Huntington's disease
    Pazos, M. R.
    Sagredo, O.
    Fernandez-Ruiz, J.
    CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (23) : 2317 - 2325
  • [6] Evidence for a disorder of locomotor timing in Huntington's disease
    Bilney, B
    Morris, ME
    Churchyard, A
    Chiu, E
    Georgiou-Karistianis, N
    MOVEMENT DISORDERS, 2005, 20 (01) : 51 - 57
  • [7] Longitudinal evaluation of cognitive disorder in Huntington's disease
    Snowden, J
    Craufurd, D
    Griffiths, H
    Thompson, J
    Neary, D
    JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY, 2001, 7 (01) : 33 - 44
  • [8] Huntington's disease
    Ha, Ainhi D.
    Fung, Victor S. C.
    CURRENT OPINION IN NEUROLOGY, 2012, 25 (04) : 491 - 498
  • [9] Beyond The Movement Disorder : OCD in Huntington's Disease
    Neeharika, Sagi Lakshmi
    Reddy, Suresh
    Surekha, G.
    Pradyumna, C.
    INDIAN JOURNAL OF PSYCHIATRY, 2025, 67 : S188 - S188
  • [10] Is Huntington's disease a neurological or psychiatric disorder? Case report
    Dubas-Slemp, Halina
    Tylec, Aneta
    Michalowska-Marmurowska, Halina
    Spychalska, Katarzyna
    PSYCHIATRIA POLSKA, 2012, 46 (05) : 915 - 922